Drug Trial Radar · NCT07814417
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate how well olomorasib is tolerated and what side effects may occur when combined with other interventions in participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutant, locally advanced colorectal cancer (CRC) that cannot be removed with surgery or has spread to other parts of the body. Blood tests will be performed to investigate how the body processes the study drug.
Conditions
- Colorectal Neoplasms
Interventions
OlomorasibDrug
Administered orally
CetuximabDrug
Administered IV
OxaliplatinDrug
Administered IV
Leucovorin/levofolinate calciumDrug
Administered IV
5-fluorouracilDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Baseline until Disease Progression (PD) or Participant Stops Study (Estimated up to 15 Months)
- Progression-Free Survival (PFS) Per RECIST v1.1Time frame: Baseline to the Date of First Documented Progression of Disease or Participant Stops Study (Estimated up to 21 Months)
Locations
18 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
USC Norris Comprehensive Cancer Center
Los Angeles, California
AdventHealth Orlando
Orlando, Florida
Dana-Farber Cancer Institute
Boston, Massachusetts
START Astera, LLC
East Brunswick, New Jersey
Texas Oncology - Central South
Austin, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Inova Health Care Services
Falls Church, Virginia
University of Wisconsin - Carbone Cancer Center
Madison, Wisconsin
Beijing Cancer hospital
Beijing, China
Hospital del Mar
Barcelona, Spain
Hospital Universitari Quiron Dexeus Barcelona
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Complejo hospitalario de Jaen
Jaén, Spain
Clinica Universidad de Navarra - Madrid
Madrid, Spain
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Spain
Hospital Universitario Marques De Valdecilla
Santander, Spain
Hospital Clinico Universitario de Santiago
Santiago de Compostela, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.